Can RAD1901 Be Used in Breast Cancer Patients with ESR1 Mutations?

Can RAD1901 Be Used in Breast Cancer Patients with ESR1 Mutations?

User Photo
AnnualMeeting2017

3 years
729 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses common questions he's asked regarding his study on the use of elacestrant (RAD1901) for ER+ advanced breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer
Up Next Autoplay
>